Welcome to Fusion
Dear GW Community and Fellow Research Enthusiasts,

FUSION
EDITORIAL
BOARD
From left: Matt Holzner, MSII;
Neena Passi, MSII; Monica Passi,
MSI; Kerri Vincenti, MSII; Yasmin
Akbari, MSII; Justin Ertle, MSII;
and Thomas Zaikos, MSII.

As part of our commitment to fostering student
interest in research, the William Beaumont
Medical Research Honors Society at GW’s School
of Medicine and Health Sciences (SMHS) is proud
to introduce the 2012 edition of Fusion — a
student-run research journal that serves as a forum
for students to share their research experiences with
the GW medical community.
This year’s edition focuses on the theme of
putting basic science research into clinical practice.
Medicine is an incredibly dynamic and rapidly
evolving field. At the same time, basic science is
identifying new molecular pathways, genetic polymorphisms in disease, and targeted pharmaceutical
therapies at an impressive rate. While these developments are aimed at advancing the medical field,
the integration of these innovations into clinical
practice also poses a unique challenge for today’s
health care professionals.
Never before has the collaboration and coordination of researchers and health care practitioners
been more important. As future medical professionals it is imperative that we seek to continue
to integrate these dynamic aspects into our own

practice. However, learning these skills most often
requires us to immerse ourselves in enriching
experiences outside the classroom, and it is these
endeavors that Fusion highlights. This publication
features a “fusion” of clinical, basic science, and
public health research, reflecting the experiences of
a number of enthusiastic and dedicated members of
the SMHS student body. We hope that as you enjoy
reading the following articles you are inspired to
seek out opportunities that will help strengthen
your own skills as future health care professionals.
Lastly, we would like to thank all of our authors
and artists who help to make Fusion a great success
each year. We also extend our many thanks to our
faculty advisor, Vincent A. Chiappinelli, Ph.D.,
interim associate vice president for Health Affairs
and associate dean of SMHS, and the Office of the
Dean for their generous support, and to SMHS
Office of Communications and Thomas Kohout
and Michael Leong for making Fusion a reality.
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Letters
Following the Route to Discovery
I
a m
thrilled to
congratulate the students of the
William H.
Jeffrey S. Akman,
Beaumont
M.D. ’81, GME ’85
Medical
Interim Vice
Research
President for Health
Honor
Affairs, Dean, School
Society for
of Medicine and
their dediHealth Sciences
c at ion to
research
and their willingness to take
on the challenge of producing
the sixth edition of their

scientific journal, Fusion. This
publication is an example of
how our students frequently
go beyond their didactic and
clinical requirements to delve
into finding the root causes
of disease and discovering
new therapies. The research
published on these pages is a
culmination of a wide-range
of research interests, a lot of
hard work, and desire to push
the needle forward to ensure
that health professionals have
the information they need to
make informed decisions.
As an institution, GW is

committed to research and
the School of Medicine and
Health Sciences is a leader in
those efforts. I am extremely
proud of our faculty for fostering our student’s desire to
learn, as well as for identifying
opportunities for continued
research in an environment
where it is not always easy
to attain financial support.
As our health care system
evolves to meet the needs of
the future, research and discovery will continue to grow
in importance. The lessons
medical students learn today
will lay the foundation for
successful medical careers in

the years to come.
GW’s Beaumont Society
was established at the School
of Medicine in 1935 to
encourage student research.
The Society promotes the
development of research
knowledge, skills, and experiences while gaining an appreciation of the influence of
research on the current and
future practice of medicine.
Once again, congratulations to the Beaumont Society
and its faculty advisors on
a fantastic publication and
I wish you the best in your
future scientific endeavors.

Enthusiasm and Endurance are the Keys to Academic Achievement
By the
time they
reach medical school,
student
have
David Leitenberg,
already
M.D., Ph.D.,
achieved a
associate professor,
significant
Microbiology, Immulevel of
nology and Tropical
academic
Medicine; Pediatrics;
success
Pathology
a nd have
developed
unique
interests that set them apart
as individuals. It is critical
that as students progress
through medical school and
post-graduate training there
be opportunities to preserve
and foster the development of
these and additional interests.
One way this is done is by
encouraging the pursuit of
individual research experiences, be they basic, clinical,
or translational.
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There are many ways to
achieve a meaningful research
experience, from a two-month
summer experience to a
decade of Ph.D. and post-doctoral training. In reflecting
on my own career path as an
M.D.-Ph.D. student, it is clear
that the most important feature was not to be the student
who got the highest test scores
(that was never true), but to
simply have the endurance
and enthusiasm to persevere
through an extended period
of training, and to tolerate the
inevitable failures and critical
reviews inherent in research.
My primary motivation
was not dependent upon
whether a given project was
clinically relevant. The potential clinical impact of basic
science research, as well as
clinical research, is difficult if not impossible to predict. I believe that the most
important motivation for

those pursuing research is an
inherent curiosity and enthusiasm for learning how things
work or determining how to
make things work better.
Students come to medical
school with that curiosity and
enthusiasm to learn about
how the complexities of biological systems are related to
clinical care. Unfortunately,
it’s often lost, partly because
of the way we teach in the
pre-clinical years and also
because as students become
more exposed to clinical
decision making it becomes
self-evident that a lot of the
biomedical science knowledge that they committed to
memory has relatively little
relevance to patient care.
Because of this disconnect,
one may justifiably ask why
there is such an emphasis
on basic biology in medical
school. I think the answer
partly lies in the ability of

scientific teaching to foster
critical thinking and intellectual curiosity. As students
go on in clinical practice,
whether this is combined with
a research interest or not, it is
important that they are intellectually equipped to manage
the more atypical patient
presentations and critically
challenge standard ways of
treating patients.
It is here that those students involved in research
and who have contributed to
Fusion have a special role. You
can serve as role models for
your peers by demonstrating
a commitment to intellectual
curiosity. And perhaps, with
enthusiasm and perseverance,
you will develop the skills
and opportunity to devise
new approaches to clinical
care and challenge some of
the more counter-productive
aspects of the current practice
of medicine.

Fusion ✦ 2012

Perspectives
The Use of Ayahuasca Among the Kichwa of Ecuador: The Potential Dangers
of Mixing Western Pharmacotherapy and Traditional Shamanistic Medicine
Ayahuasca
[aja’waska] is a
hallucinogenic
beverage that
i s m a d e f r om
two indigenous
plants from
Alissa McInerney, MSII
t he Nor t hwest
Amazon region,
especially by the Kichwa tribe of Ecuador.
Shamans in these regions have used the
elixir for centuries, claiming it has
diagnostic and curing effects, in addition to its psychedelics effects believed
to serve as a route to the supernatural
realm. Shamans of the community are
very knowledgeable in its usage, as well
as other Amazonian medicinal plants;
however, until recently, Western medicine was not readily available. With the
recent construction of a road connecting
the community to other small communities and the river launch point to the
city, there are concerns of the potential
blending of modern pharmacotherapy
with traditional medicinal plants such
as Ayahuasca.2
Studies of this brew have isolated
its active substances and derivates, two
of which are N,N-dimethyltryptamine
(DMT) and a plant alkaloid from the
β-carbolines. DMT is a natural psychoactive indolealkylamine, a non-selective
serotonin 5HT agonist. It has a high
affinity for serotonin 5HT1A receptors,
while the active metabolite bufotenine
has higher affinity for 5HT2A. The
active metabolite occurs as a result of
metabolism by the cytochrome P450
system CYP2D6. DMT is mainly inactivated through the deamination pathway
mediated by monoamine oxidase-A
(MAO-A). β-carboline alkaloid is a wellknown potent MAO-A inhibitor. Thus,
when dually ingested in the Ayahuasca
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drink, a β-carboline such
as harmaline inhibits the
breakdown of DMT and
increases the synaptic levels
of the active metabolite,
bufotenine.3
After spending several
days with the very small
and isolated Kichwa community in the Napo region
of Ecuador, I realize how
mixing traditional shamanistic medicine and
Members of the Kichwa community of Rio Blanco in a traditional
western pharmacotherapy
performance.
could lead to potentially
fatal consequences. The
adverse reactions that could occur with
improved access to Western medical care
Ayahuasca or any other medicinal plant
for the Kichwa people and the influx of
therapy because he was never exposed to
Western tourists, students, and volunsuch Western pharmacotherapy before.
teers, poses a great risk of mixing the use
Therefore, it is in my opinion that shaof Ayahuasca with their current pharmamans of the indigenous communities in
cotherapy. Common drug interactions
the Napo region of the Amazon receive
of concern are selective serotonin reupsome education about pharmacotherapy
take inhibitors (SSRIs) among others.
of the modern world and about fusing
This class of drugs is commonly prethe indigenous shamanistic medicine
scribed in the western world and when
with modern western medicine. It is also
taken with Ayahuasca can cause a toxic
important that travelers and physicians
increase in serotonin causing serotonin
3
treating those who may be traveling
syndrome. This adverse drug reaction
to indigenous communities be made
can have mild to life threatening sympaware of the potential risks including
toms caused by increased serotonergic
drug-drug interactions before taking
activity. The classic clinical description
Ayahuasca or other medicinal plants.
includes changes in mental status, autonomic hyperactivity, and neuromuscular
REFERENCES:
abnormalities. However, symptoms can
1. Boyer Ew, Shannon M. (2005). The Serotonin
range from diarrhea, tremor, myocSyndrome. N Engl J Med. 352:1112–1120.
lonus, dilated pupils, hyperthermia, and
2. Mckena D. (2004). Clinical Investigations
increased blood pressure and heart rate
Of The Therapeutic Potential Of Ayahuasca:
that may eventually lead to metabolic
Rationale And Regulatory Challenges. Pharmacology And Therapuetics. 102, 111–129.
acidosis and shock. It is often difficult to
diagnose because of the range of severity
3. Shen Hw, Jiang Xl, Winter Jc, Yu Am. (2010).
Psychedelic 5- Methoxy-N,N-Dimethyltryptof the symptoms.1
amine: Metabolism, Pharmacokinetics, Drug
A fter speaking with a K ichwa
Interactions, And Pharmacological Actions.
shaman, it was very clear that he
Current Drug Metabolism. 11,659–666.
was unaware of any interactions or
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The Importance of Pediatrics in Disaster Planning
During the 2010
E a r t hqu a ke in
Haiti, children
under the age of
12 accounted for
65.9 percent of all
deaths; they were
eleven times as
Ireal Johnson, MSII
likely to die due
to sustained injuries, and twice as likely to die due to
illness compared to adults.1 There is a
disparity in options for treating children
that becomes clearer in disasters that
largely affect the pediatric population,
necessitating a re-evaluation and restruc-

felt less prepared and more uncomfortable with pediatric emergencies versus
emergencies in adults.
Children are more vulnerable during
disasters because they have important biological differences that make
them more susceptible to insults like
disease, physical injury, and dehydration.3 Children also present special
challenges during disasters, such as
separation from caregivers and inability
to relay important medical information.
Reunification may be more difficult to
achieve for younger children since many
are unable to identify themselves, their
parents or their caregivers. Additionally,
many hospitals are not
Once a disaster involving children has adequately equipped to
handle the large variaoccurred, health care professionals should tions in sizes that children go through as they
determine and manage surge capacity by develop. This equates to
sub-standard quality of
using an effective pediatric triage system. treatment, especially for
smaller children, since
turing of current strategies in pediatric
they are the least compatible with readily
emergency management.
available adult-sized equipment.
Emergency management is the disThere are some things that can be
cipline of preparing for and avoiding
done to help address these problems. In
risks that have large catastrophic consepreparation for a disaster, health care
quences. It involves a coordinated effort
professionals should discuss emergency
from multiple professional fields with
plans with patients and their families
the main goal of public safety followed
and suggest assembling a disaster tool
by the protection of resources and propkit.4 Health care professionals should be
erty. There are four phases that work in
involved with organizations that perform
sequence to reach this goal: mitigation,
drills in order to increase and test their
preparedness, response and recovery.
disaster response ability. They should
Many resources are available that outline
also try to advocate for pediatric-specific
health care planning and mitigation in
protocols in disaster planning. This will
response to a disaster event. However,
educate all types of health professionals
the majority of these plans focus on care
on the basics of treating children and
for adults and wrongly assume that the
increase awareness on the differences
same strategies will work for children.
between pediatric and adult medicine.
In a study of pediatric surgeons, 77 perOnce a disaster involving children has
cent felt, “definitely responsible” to help
occurred, health care professionals
during a disaster, yet only 24 percent
should determine and manage surge
reported feeling “definitely prepared.”2
capacity by using an effective pediatric
Many emergency physicians have also
triage system. Determining the level
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of care each patient needs improves
allocation of resources; with more
attention and resources being spent on
acutely injured and treatable victims.4
Professionals should also understand
the established communication system
in order to increase the effectiveness of
their efforts. Improved communication
would also assist in reunification between
separated children and families. Patients
and their families should get adequate
support on how to cope after a disaster.
It is important for experienced professionals to work with children to guide
and provide developmentally appropriate
ways of dealing with their feelings.2
There is a widespread lack of confidence and comfort in treating ill or
injured children among health care
professionals. It is important to address
the discomfort and disparities in treating
injured children as they make up a
quarter of the U.S. population. Ideally,
these suggestions will increase awareness and improve pediatric disaster care.
Future studies should determine the necessary steps to implement pediatric specific procedures and policies in disaster
preparedness and planning.
For more information about pediatric
emergency management, visit www.
pedsem.com.

REFERENCES:
1. Kolbe AR, Hutson R A, Shannon H, et al.
Mortality, crime and access to basic needs
before and after Haiti earthquake: a random
survey of Port-au-Prince households. Medicine,
Conflict & Survival Vol 26, Iss. 4, 2010.
2. Ablah E, Tinius AM, Konda K, Pediatric
emergency preparedness training: are we on a
path toward national dissemination? J Trauma.
2009 Aug;67(2 Suppl):S152-8.
3. Gausche-Hill, M. Pediatric disaster preparedness: are we really prepared? Journal of TraumaInjury Infection & Critical Care Vol. 67, Iss. 2
Aug 2009; S73-S76.
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and mass casualty incidents. Pediatric Emergency Care, 4, 1 1988; 4.
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Basic Science
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Radiosensitization of Melanoma Cell
Using Molecular Mutant B-Raf Drug Inhibitor◆GSK2118436
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Melanoma is an
aggressive form
of c a nc er t hat
has an increasing
incidence in
the United
States.1 Patients
Bradley T. Anderson, MSII
with metastatic
Advisor: Erik P. Sulman,
melanoma
M.D., Ph.D., The
commonly
University of Texas MD
d e v e l o p br a i n
Anderson Cancer Center
metastases. 2 An
activating valineglutamate substitution at position
600 of the B-RAF protein has been
implicated in approximately 50 percent
of melanoma cancers. 3 The B-R AF
protein is a serine/threonine protein
kinase of the RAS-RAF-MEK-MAPK
signaling pathway involved in growth
and proliferation. GSK2118436 is a
molecular inhibitor that selectively
binds and blocks the activity of mutant
B-RAF proteins. Early clinical trials
show that GSK2118436 may control
and reduce brain metastases from
melanoma.4 Primary and secondary
drug resistance has been observed in
clinical trials of B-RAF drug inhibitors
such as GSK2118436.5 The effects of
combinatorial treatment of melanoma
brain metastases with GSK2118436 and
ionizing radiation therapy are currently
unknown. The combined therapy could
be toxic, neutral, additive or synergistic.
By determining if GSK2118436 can
increase the sensitivity of radiation
resistant melanoma cells to ionizing
radiation treatment, this study assesses
the capability of GSK 2118436 to
synergistically kill or radiosensitize
human BRAF mutant melanoma cell
lines.
Clonogenic survival assays were
performed to assess in vitro cell survival
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FIGURE 1: Melanoma Cell Survival Curves. Survival curves for A375, WM35, WM2664, and SKMEL5

performed at 0-8 Gy of ionizing radiation showing the relative radiosensitivity of human melanoma cancer cell lines.
The highest survival fraction at 2 Grays (SF2) was 0.91 for WM35. The lowest SF2 was 0.48 for WM2664.

following increasing doses of radiation
(0–8 Gray or J/Kg). This assay establishes
the relative sensitivity to radiation of
the following BRAF mutant cell lines
harvested from human melanoma
tumors: A375, WM2664, WM35, and
SKMEL5. Radiosensitization of cell
lines was determined by comparison of
survival with and without the B-RAF
inhibitor, GSK2118436. Molecular
inhibition of mutant B-R A F was
confirmed by immunoblot analysis.
BRAF mutant melanoma cell lines
showed varying radiosensitivities to
radiation treatment. Figure 1 shows the
results of the radiation clonogenic assay
establishing a radiosensitivity baseline.
The radiosensitivity was determined
with the cell lines listed in order of
decreasing radiosensitivity: WM2664 >
SKMEL5 > A375 > WM35. WM2664
was the most sensitive to radiation
with the highest survival fraction after
2 Gray (SF2). WM35 was the most
resistant to radiation with the lowest

SF2 value. A375 and WM35 were
selected as candidates for examining
radiosensitivity effects of combinatorial
GSK2118436 and radiation therapy.
The results of this combinatorial therapy
are shown in Figure 2. The survival
fraction decreased significantly with low
dose GSK2118436 combination in the
radiation resistant cells (WM35). A375
are semi-radiation sensitive cells and the
response to B-RAF inhibitor was not as
dramatic as seen in the radioresistant
line WM35.
The B-RAF inhibitor GSK2118436
increases radiation sensitivity in the
radiation resistant, mutant BR AF
melanoma cancer cell lines. Our results
conf irm that melanoma cell lines
demonstrate variable sensitivity to
radiation therapy. Cell lines that were
more radioresistant were more effectively
radiosensitized by inhibition of mutant
B-R A F by GSK 2118436. Further
Continued on p. 6
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Cold Plasma Therapy as a Novel Chemotherapeutic Strategy
Plasma, the fourth
state of matter,
is composed of
partially ionized
ga s conta ining
electrons, excited
molecules, free
radicals and ions.1
Jacob Kirsch, MSII
Advisor: Anthony Sandler,
Historically,
M.D. Children’s National
plasma could
Medical Center
o n l y
b e
produced at high
temperatures or in vacuums, however,
recent advances in plasma physics
have led to the production of plasma
at room temperature.2,3 Non-thermal
atmospheric plasma, or “Cold Plasma”
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is produced by applying a high voltage
killing tumor cells in both in vitro and
electric field to a plume of compressed
in vivo mouse models of neuroblastoma.
gas. While theoretically any gas or
We therefore sought to advance these
mixture of
gasses can
Cold plasma treatment (CPT) can potentially
be used, our
group used
be used in cancer therapy by generating reactive
helium due to
the advantages
ion species that may induce tumor cell apoptosis.
of it being
monatomic
and chemically
inert. Cold plasma treatment (CPT) can
findings by evaluating the effects of cold
potentially be used in cancer therapy
plasma in human neuroblastoma and
by generating reactive ion species that
normal fibroblast cell lines.
may induce tumor cell apoptosis. Our
In this study, we attempted to
initial studies demonstrated efficacy in
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elucidate the chemotherapeutic effects
of CPT by evaluating its effects on
IMR-32 human neuroblastoma cells
and human fibroblasts (ATCC 895.
sk). A constant dose of CPT was
administered for 30, 60, and 120
seconds, respectively. Cell apoptosis
was analyzed by f low cytometry at
four different time points following
treatment with CPT: immediately, 24
hours, 48 hours, and one week. Normal
human fibroblasts were chosen to serve
as a negative control for comparison.
Staining for apoptosis (annexin V-FITC)
as well as cell death (7-AAD) allowed
us to differentiate between necrotic
cells, which died through mechanisms
unrelated to CPT, and cells that were
induced to undergo apoptosis as a direct
result of CPT. The potential utility of
CPT as a chemotherapeutic agent is
dependent on its ability to produce the
latter.
Our study showed that CPT of
neuroblastoma cells induced a three to
six-fold increase in apoptosis compared
to controls. CPT induced a doseresponse effect in the tumor cells,
decreasing cell viability by up to 89
percent 24 hours after treatment (data
not shown) and 98 percent 48 hours after
treatment (Figure 1). Conversely, CPT
was largely ineffective in eliciting an
effect on human fibroblasts; these cells
maintained their viability compared
to untreated controls both 24 hours
and 48 hours post-treatment (Figure
2). This effectively demonstrated that
CPT can induce apoptosis of human
neuroblastoma cells, without affecting
norma l human f ibroblasts. Cold
plasma therefore represents a potential
emerging adjunct in cancer therapy,
as demonstrated by its selective and
effective in vitro targeting of human
neuroblastoma. The mechanism of this
tumor selectivity is currently still under
investigation, however it is believed to be
mediated by the generation of reactive
oxygen species.

BASIC SCIENCE

Annexin and 7AAD Staining in IMR-32 Cells Exposed to Cold Plasma
for Varying Amounts of Time — 48-hours Post-Treatment
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FIGURE 1: Annexin and 7AAD staining in IMR-32 cells 48 hours after treatment with cold plasma for varying
amounts of time.

Annexin and 7AAD Staining in Fibroblasta Exposed to Cold Plasma
for Varying Amounts of Time — 48-hours Post-Treatment
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FIGURE 2: Annexin and 7AAD staining in Fibroblasts 48 hours after treatment with cold plasma for varying
amounts of time
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Characterization of the Role of Lman1 in Retinal Degeneration
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FIGURE 1: Comparison of NRL antibody ChIP DNA to IgG control ChIP DNA showed a 15-fold difference
in the expression of Lman1.

B

16
14
12

Fold Change
(WT/NRL KO)

The process of
vision begins at
the photoreceptors in the retina,
w h ic h prov ide
nearly 30 percent
of t he sensor y
Sana Idrees, MSII
input to the brain.
Advisors: Hong Hao,
NeurodegeneraJanina Gregorski,
tive blinding disand Anand Swaroop,
eases are due to
National Eye Institute
genetic defects
Bin Zhang, Genomic
that cause
Medicine Institute, Lerner
a bn or m a l d i fResearch Institute, Cleveferent iat ion or
land Clinic Foundation
homeostatis of
retinal photoreceptors, and such defects are the primary
cause of visual impairment in diseases
of the retina. The neural retina leucine
zipper (NRL) transcription factor is
a key regulator of rod photoreceptor
differentiation and homeostasis. NRL
functions as a molecular switch to
produce rod photoreceptors from postmitotic retinal precursor cells.1 Lman1
encodes ERGIC-53, a protein mediating the transfer of a subpopulation of
glycoproteins from the ER to the Golgi
complex.2 ERGIC-53 has a secondary
function in glycoprotein quality control
and it is ubiquitously expressed.3 We
identified the Lman1 gene as a direct
transcriptional target of NRL. To identify the potential role of Lman1 in retinal
degeneration, we investigated its regulation and function in rod photoreceptors
using Lman1 knockout mice.
Chromatin immunoprecipitation
followed by real-time quantitative
polymerase chain reaction (ChIPqPCR) and enhancer analysis of the
Lman1 enhancer element were used to
validate the interaction between NRL
and Lman1 promotor sequences. ChIPqPCR and enhancer analysis detected
the Lman1 promotor as a direct target
of NRL.
Physiologic relevance of Lman1
i n t he re t i n a w a s te s te d u si n g
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FIGURE 2: A 15-fold difference in Lman1 expression was observed between WT and NRL knock out mouse retinas.

immunohistochemistry (IHC) in Lman1
knockout mice. Retinas were collected
from Lman1 -/- mice at 2 months and
6 months of age. The retinas were
sectioned, and IHC was performed
against the Golgi markers GM130
and Grasp65, glial marker GFAP, and
the rod photoreceptor visual pigment
rhodopsin.
IHC showed reduction in Grasp65
and rhodopsin in 2 month and 6 month
old Lman1 -/- mice compared to WT,

whereas no siginificant difference in
GFAP was observed. IHC against
GM130 a lso showed signif ic a nt
reduction in 2 month old Lman1 mice
compared to WT.
Our results suggest that Lman1 has
an important role in rod photoreceptor
development and homeostasis. Function
tests will be conducted to evaluate the
retina of Lman1 -/- mice through light
damage studies and electroretinography
analyses.

Fusion ✦ 2012

REFERENCES:

Enhancer Analysis of Lman1

1. Cunningham MA, Pipe SW, Zhang B, Hauri
HP, Ginsburg D, K aufman RJ. (2003).
LMAN1 is a molecular chaperone for the
secretion of coagulation factor VIII. Journal of
Thrombosis and Haemostasis. 1:2360–2367.

3. Zhang YC, Zhou Y, Yang CZ, Xiong DS.
(2009). A review of ERGIC-53: Its structure,
functions, regulation, and relations with
disea ses. Histolog y and Histopatholog y.
24:1193–1204.

16
12

Normalized Luciferase
Activity (mNRL/Vector)

2. Swaroop A, K im D, Forrest D. (2010).
Transcriptional regulation of photoreceptor
d e ve lopme nt a nd home o s t a si s i n t he
mammalian retina. Nature. 11:563–576.

C

8
4
0
Empty
Vector

Lman1

Non ChIP
Region

Non ChIP
Region

Constructs Cotransfected with mNRL

FIGURE 3: There was a significant difference in the normalized luciferase activity in HEK293T cells cotransfected
with a Lman1 enhancer construct and mouse NRL (mNRL) compared to cells cotransfected with a control vector and
mNRL. Non ChIP regions (controls) showed no significant luciferase reporter activity.

Developing a 3D Glandular In Vitro Model from Human Airway Epithelial Basal Cells
Submucosal
glands — invaginations of the surface epithelium
in cartilaginous
mammalian airw ay s — a re a
major source of
Maureen Banigan, MSII
Advisor: Xiaofang Wu,
mucus producM.D., Children’s National
tion in the upper
Medical Center
respiratory tract.
Submucosal
glandular (SMG)
hyperplasia is a primary histopathologic feature in obstructive respiratory
pathologies — such as cystic fibrosis
and chronic rhinosinusitis — associated
with mucus hypersecretion and obstruction of the sinonasal tract.1,2 While
the morphogenesis of SMGs during
fetal development is well described,3
the underlying mechanisms that lead
to invagination of the epithelium and
differentiation of epithelial cells to glandular cells with ductal tubules and acini
are unknown. Glandular hyperplasia
in respiratory tract mucosa is markedly
understudied, reflecting the lack of an in

B

A

FIGURE1: Brightfield pictures of HNE cells on D18. (A) HNE cells cultured on growth-factor reduced Matrigel
proliferate into glandular-like acini. (B) HNE cells form tubule structures in collagen I matrix.

vitro cell model system whereby respiratory tract epithelial cells differentiate
into glandular cells.
The current paradigm in lung
biology is that there are progenitor cells
in respiratory tract epithelium poised to
facilitate epithelial repair and remodeling. These cells are capable of undergoing epithelial invagination into the
underlying basement matrix that results
in the formation of SMG with ductal
tubules and acini. The SMG progenitor

William H. Beaumont Medical Research Honor Society

cells in both mice and humans have been
identified as basal cells (BCs) within the
surface airway epithelium of the lower
respiratory tract.4,5 Predictably, the
progenitor cells in nasal and sinus epithelium are also basal cells, but limited
studies exist on BCs isolated from the
upper respiratory tract. We hypothesize
that BCs differentiate to form glands in
a three-dimensional extracellular matrix
Continued on p. 10
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FIGURE: (A) Growth kinetics of HNE cells with and without exposure to 100-ng/mL FGF9. The results represent the mean values from three different experiments. (B) Ten

brightfield images of HNE acini were taken every five days until day 20. Acinar areas were measured in 25 individual acini by Image J (NIH). Fold changes of HNE acinar average
area after exposure to FGF-9 is shown. Values are expressed as means of acinar sizes + standard error (SE) of three experiments. *indicates significant difference at p<.05

Continued from p. 9
and are triggered by inf lammatory/
immune response mediators and growth
factors to produce glandular hyperplasia
in disease states. To test this hypothesis,
we developed an in vitro 3D system
wherein BCs from primary epithelial
cells differentiate into glandular structures when grown on different basement
membrane matrices.
Fluorescent activated Cell Sorting
(FACS) analysis of purified human nasal
epithelial (HNE) cells and human bronchial epithelial (HBE) cells derived from
human airway epithelium indicated
that 98 percent of cells were basal cells
and immunofluorescence (IF) staining
for basal cell markers supported this
finding. We found that the morphological differentiation of BCs in in vitro
culture is dependent upon extracellular
matrix conditions. While HSE BCs
differentiate into glandular acini when
overlaid on Matrigel®, they differentiate
into glandular tubules when embedded
in collagen (Figure 1). Both glandular
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acini and glandular tubules formed by
HNE cells in vitro expressed in vivo
markers of mucous and serous glandular
cells. Exposure of HNE basal cells to
EGF, FGF7, and FGF9 significantly
enhanced their proliferation rate, suggesting that growth factors may play an
important role as positive regulators of
the morphogenesis and differentiation
of submucosal glands in respiratory tract
mucosa (Figure 2). Although statistically
significant, the increased HNE acinar
size seen after exposure to inflammatory mediators (CXCL5, CXCL13, and
GM-CSF) was small.
Our developed in vitro glandular
acinar model is a useful model for
studying the effects of growth factors and other mediators on HSE and
HNE glandular proliferation and
differentiation. The use of basal cells,
which can be cultured in a chemically
defined medium, permits analysis in a
controlled model system of the activity
of growth factors and inflammatory
mediators added to the culture. Further
investigation into the role of immune/

inflammatory response mediators and
growth factors in de novo gland development will allow identification and
eventual circumvention of the mechanisms that lead to SMG hyperplasia
with subsequent mucus hypersecretion.
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Translational
Diagnosis of Coronary Artery Disease by Deep Sequencing of Blood
Transcript Fold Elevation in CAD (>20 Percent Stenosis)

Cardiovascular
d i s e a s e i s t he
leading cause
of death in the
United States.1
Coronary artery
disease (CAD), in
which atheroscleJustin Ertle, MSII
rotic plaque builds
Advisor: Tim McCaffrey,
up and obstructs
Ph.D., GW School of
the arteries supMedicine and Health
plying the heart,
Sciences
affects over 16.5
million people in
the United States. 2 Nearly 500,000
people in the U.S. are newly diagnosed
with CAD each year.2
The current gold standard for
diagnosing CAD is coronary angiography
using coronary artery catheterization.
However, only 60 percent of patients
u ndergoing d ia gnost ic corona r y
catheterization have obstructive CAD
(≥50 percent stenosis of left main
coronary artery or ≥70 percent stenosis
of major epicardial vessel), while 39
percent of patients undergoing elective
coronary catheterization have no CAD
(<20 percent stenosis in all vessels).3
Given the risks associated with coronary
catheterization and the expense of this
procedure, it would be valuable to
develop an alternative highly predictive
test for CAD.3,4
There is evidence that specif ic
changes in gene expression accompany
CAD.2,5 Several studies have identified
differentially expressed gene transcripts
in blood samples associated with CAD,
raising the possibility that detecting
changes in transcript expression in
patient blood samples may be a feasible
means of predicting the presence of
CAD.2,5 Therefore, transcript expression
profiles of differentially expressed genes
are the potential basis of a blood-based
diagnostic test for CAD.
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FIGURE: FOLD ELEVATION OF SELECTED GENE TRANSCRIPTS IN CAD:
Fold elevation of selected gene transcripts in patients with CAD (>20 percent stenosis) relative to the transcript
expression level of the same gene in patients without CAD (0 percent stenosis). (p < 0.01)
PLD2: Phospholipase D2
ESR2: Estrogen Receptor ß
SHMT2: Serine Hydroxymethyltransferase 2 (a/b = splice isoforms)

To investigate the possibility of
developing a test for CAD based on
differential transcript expression, we
used next-generation sequencing of
blood sample R NA (R NA-seq) to
identify Transcripts Associated with
CAD (TRACs). While previous studies
have used microarray-based methods
to identify differential gene expression
in CAD, we used RNA-seq because
it provides the advantages of directly
quantifying all known transcripts and
allowing analysis of splicing and allele
usage.5
Here, we show that RNA sequencing
of blood samples identifies TRACs in
our patient population. Blood samples
were collected from patients without
previously diagnosed CA D about
to undergo non-emergency cardiac

catheterization. As a midpoint analysis,
from our coronary catheterization
cohort we identified 10 patients with
significant CAD (>20 percent stenosis
of one or more arteries) and 10 patients
without CAD (0 percent stenosis).
These patients were matched for age
and gender; no significant differences
existed between groups for risk factors
such as blood pressure, BMI, or diabetes.
RNA was extracted from these blood
samples and sequenced on the Helicos
sequencing platform.
These preliminary RNA-seq digital
gene expression data identified 151
gene transcripts differentially expressed
in patients with stenosis (> 1.5 fold
change) passing a t-test corrected for
Continued on p. 12
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in the SHMT2(b) isoform, illustrating
the ability of this method to assess
expression of splice variants.
multiple testing (p < 0.01). These 151
These preliminary results demonTRACs included 17 of 23 transcripts
strate identification of 151 gene tranassociated with CAD identified in a
scripts differentially expressed in patients
2008 microarray-based study.5 The
with CAD using RNA sequencing. After
analysis of all enrolled
patients is complete,
[T]ranscript expression prof iles of
the next planned step
differentially expressed genes are the
in this ongoing study is
to use these TRACs to
potential basis of a blood-based diagnostic
train a Support Vector
Machine classification
test for coronary artery disease.
algorithm to identify
CAD in new patient
fold elevation of Phospholipase D2,
samples. This expression profile algoEstrogen Receptor ß, and Serine
rithm will be used to develop a bloodHyd rox y me t hy lt r a n s fer a s e g ene
based rapid PCR array or ELISA test
transcripts in CAD are highlighted
to provide a rapid, minimally invasive
in the Figure. Of particular interest
CAD detection test. The possibility
is the greater than 4-fold increase in
of preventing needless catheterizations
expression of the SHMT2(a) isoform,
with this blood test has the potential
and the greater than 4-fold decrease
Continued from p. 11

to improve patient outcomes while
increasing time and cost efficiency of
CAD diagnosis.
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Identifying CSF Biomarkers of Oxidative Stress in Patients with Multiple Sclerosis
Multiple Sclerosis
(MS) is an
immune-mediated disorder
of t he c ent r a l
nervous system
(CNS) that leads
Joseph Pawlowski, MSII
to inflammation,
Advisors: Pradeep Shukla,
demyelination,
and Bibiana Bielekova,
and axonal degenPh.D., National Institute
eration. Although
of Neurological Disorders
the cause of
and Stroke, NIH
MS remains
unk nown, it is
believed that reactive oxygen species
(ROS) released from macrophages and
microglial cells in the CNS react with
myelin to result in the pathology seen
in MS. Specifically, ROS react with
myelin fatty acid side chains resulting
in cell damage and a breakdown in
Blood Brain Barrier (BBB) integrity.1
Two end-products generated from
the lipid peroxidation of myelin are
4-Hydrox ynonena l (4-HNE) and
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		CIS
Number (n) 10
Female, n 6
Median Age (years) 39.5
		(20-57)

NIND
38
30
48
(27-65)

OIND
20
8
39
(40-62)

PPMS
38
19
52
(20-67)

RRMS
74
42
38.5
(18-68)

SPMS
12
6
53
(32-67)

ALL
192
111
45.5
(18-68)

TABLE: Demographics and clinical characteristics of patients and controls.
8-Isoprostane (8-IsoP), and are therefore
expected to be increased in the CNS of
MS patients.2 Uric acid is an antioxidant
that would be expected to increase in the
serum of MS patients as a host defense
mechanism against oxidative stress.
The goal of this study was to
identify biomarkers of oxidative stress
in the cerebrospinal f luid (CSF) of
MS patients. The discovery of a novel
biomarker whose levels correlate with
the amount of oxidative damage in the
CSF would offer a quantifiable entity
that could be used as a diagnostic tool
and as a measure of disease progression.
This study investigates 4-HNE and

8-IsoP as potential CSF markers.
Enzyme-linked Immunosorbent
Assays (ELISA) were optimized to
quantify the concentrations of 4-HNE
histidine adducts and free 8-IsoP in
the CSF of a blinded cohort of subjects. Serum uric acid levels were also
obtained as a measure of antioxidant
activity. A total of 124 patients with MS,
10 patients with a Clinically Isolated
Syndrome (CIS) not yet classified as
MS, 38 patients with Noninflammatory
Neurologic Diseases (NIND), and
20 patients with Other Inflammatory
Neurologic Diseases (OIND) were
included. Patients were classified as
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acid were
acid showed a significant

correlation with 4-HNE levels (p=0.019; a), but did not correlate with 8-IsoP levels (p=0.697; b) (n=52).

having Primary Progressive MS (PPMS) (n=38), Relapsing Remitting
MS (RR-MS) (n=74), or Secondary
Progressive MS (SP-MS) (n=12).
4-HNE was found to be significantly
elevated in the CSF of MS patients
compared to controls (p<0.05), while
8-IsoP showed only a modest elevation.
The increase in both species supports
the proposed role of oxidative stress in
the pathogenesis of MS. In addition,

serum levels of uric acid correlated
with CSF levels of 4-HNE but not
with 8-IsoP (Figure 1). The correlation
between 4-HNE and uric acid suggests
that the two may be associated with
MS pathology; specifically, oxidative
stress causes an increase in uric acid
concentration as an antioxidant defense
mechanism.
Among MS subtypes, only PP-MS
and R R-MS showed a signif icant

increase in CSF levels of 4-HNE compared to controls, the former being
most statistically significant (Figure 2).
PP-MS is characterized by a gradual
decline in disability with no distinct
periods of remission, while RR-MS
shows periods of partial remission.3
Hence, 4-HNE levels should indeed
be highest in these patient groups
Continued on p. 14
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FIGURE 2: The absorbance of each patient sample was measured and analyzed using standard curves to determine 4-HNE and 8-IsoP concentrations. Among MS subtypes,
PP-MS and RR-MS patients had significantly higher CSF levels of 4-HNE compared to NIND controls (p<0.05; a), whereas SP-MS did not reach statistical significance. PP-MS
patients had the highest mean concentration of 8-IsoP, but no group showed a statistically significant difference in 8-IsoP concentrations compared to controls (p>0.05; b).
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compared to SP-MS patients who are
in a state of chronic remission.
CSF levels of 4-HNE were independent of both patient age and gender,
while 8-IsoP levels were independent
of gender but increased with age. This
implicates 4-HNE, but not 8-IsoP, as a
marker for patients of all demographics.

A future study already in progress
involves the development of ELISA
assays to measure additional products
of oxidative stress. CSF levels of these
products will be analyzed and compared
to the levels of 4-HNE, 8-IsoP, and
uric acid.
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A Variant in the Supervillin Gene is Associated
with Lean Muscle and Adiposity Phenotypes
Supervillin is a
205-kD F-actin
binding protein
encoded by the
SVIL gene that
f unctions a s a
linkage protein
between the celKarin Kuhn, MSII
lular actin cytoAdvisor: Laura Tosi,
skeleton and
M.D., Research Center
pla sma memfor Genetic Medicine,
brane.1 The proChildren’s National
Medical Center
tein loca lizes
within lipid-raft
domains of the plasma membrane, and
potentially functions in cellular adhesion
and motility. While SVIL is expressed in
numerous tissues, expression is highest in
striated, cardiac, and smooth muscle.2
Archivillin is a 297-kD, alternatively
spliced isoform of SVIL that is specific
to skeletal muscle tissue and myogenic
cell lines. Archivillin also binds directly
to F-actin and is associated with the
cytoskeletal protein, dystrophin, as well
as the adhesion proteins, caveolin-3,
and vinculin. It has been proposed that
archvillin may play a role in early myogenesis and muscle cell differentiation.
Additionally, it may contribute to the
integrity of the myotendinous junction,
which serves to distribute longitudinal forces developed during muscle
contraction.3
The role of the SVIL gene in skeletal
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muscle has been further explored through
its relationship to the androgen receptor
(AR). AR activation and its association
with increased muscle mass has been
previously elucidated. The SVIL gene
has been found to act as a co-regulator
of the AR in skeletal muscle, increasing
transactivation. This result indicates
that SVIL may play an important role
in muscle development and repair.
Additionally, previous studies have
suggested the potential for cross-talk
between the AR and vitamin D receptor
(VDR) mediated by co-regulators of the
AR as a mechanism for increasing VDR
transactivation. Consequently, the SVIL
gene may play a role in VDR functioning
and associated bone health.4,5

Our study sought to further describe
the relationship between the SVIL
gene and phenotypes associated with
lean muscle, bone, and adipose tissue
by examining single nucleotide polymorphisms (SNPs) that may have a
functional relationship to the SVIL gene.
We studied 155 ethnically diverse,
healthy volunteers (average age 22.05±
4.6 yrs females and 23.31 ± 5.61 yrs
males) recruited from the Bone and
Muscle Study performed at the University
of Massachusetts. We genotyped two
SNPs found in SVIL (rs36027845 and
rs10437410), and examined associations
between these SNPs and measures of
lean muscle tissue, bone mineral density,
and adiposity. Mean quantitative muscle,

Significant Results
SNP
Phenotype (units) Sex
P-value
SVIL rs36027845
% Tissue fat
M
0.0190
					
		
Total fat (g)
M
0.0175
					
		
Total lean (g)
M
0.0157
					
		
Arms lean (g)
M
0.0216
					

N: adjusted mean +
AA (N=31; 20.2 ± 1.1)
AG/GG (N=35; 23.9 ± 1.1)
AA (N=31; 16455 ± 846)
AG/GG (N=35; 19358 ± 794)
AA (N=31; 59894 ± 819)
AG/GG (N=35; 57034 ± 769)
AA (N=31; 7193 ± 140)
AG/GG (N=35; 6755 ± 131)

TABLE 1: In males, a single copy of the G allele for a SNP located near the SVIL gene (rs36027845) was associated

with decreased total lean muscle and total arm lean muscle mass, as well as increased total percent tissue fat and
total fat. No significant results were observed in females.
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bone, and adipose measurements were
compared in relation to SNP genotypes
using analysis of covariance (ANCOVA)
methods.
The SV IL gene and associated
supervillin protein play a functional
role in maintaining the integrity of
the cytoskeleton of the cell. Previous
studies have also implicated the SVIL
gene as an important co-regulator of the
androgen receptor in skeletal muscle,
and it has been suggested that SVIL may
increase transactivation of the vitamin
D receptor.4,5 Associations between the
SVIL gene and phenotypic variations in
muscle, bone, and adipose tissue have
not been previously studied.
The present study reports significant
associations between a variant in the
SVIL gene (rs36027845) and decreased
total lean muscle mass and arm lean
muscle mass, as well as increased percent
tissue fat and total body fat in males.
Pupasuite 3.1, a web-based SNP analysis

tool that is used to identify potential
functional properties of a variant, suggests this SNP affects transcription factor
binding. Our findings were sexually
dimorphic as no significant findings were
established in females. There were no
significant findings between the genetic
variants in the SVIL gene of interest and
phenotypes associated with bone.
These results are consistent with previous studies that have investigated the
role of the SVIL gene and the associated
supervillin protein in muscle development, and provide further evidence that
the SVIL gene may play an important
role in early myogenesis and regulation
of skeletal muscle development via coregulation of the androgen receptor. An
inverse relationship between skeletal
muscle and adipose tissue was observed
in males with the genetic variant, indicating that the polymorphism may also
be associated with an increased risk for
adiposity. Additional study is needed

to further elucidate the function of the
SVIL gene in skeletal muscle growth
and development as well as identify
implications in disease processes of the
musculoskeletal system.
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The Relationship Between Single Nucleotide Polymorphisms (SNPs) (rs1366594,
rs2941740, rs87938) and Phenotypic Predictors of Bone and Muscle Health
Osteoporotic
fractures cause
injuries that result
i n s i g n i f i c a nt
morbidity
a nd mor ta lit y.
Substantial
Jordan Ruby, MSIII
effort has been
Advisors: Laura Tosi, M.D.,
made to identify
and Joseph Devaney,
persons at risk
Ph.D., Research Center
for osteoporotic
for Genetic Medicine,
fracture so that
Children’s National
preventative
Medical Center
measures can
be initiated in a
timely fashion. To date, one of the
best predictors of fracture is bone
mineral density (BMD).1 If it were
possible to identify persons at high
genetic risk for developing low bone
density, preventative strategies might be

TRANSLATIONAL

employed as early as childhood.
Rivadeneira et al recently performed
a meta-analysis of five genome-wide
association studies of femoral neck and
lumbar spine BMD in 19,195 subjects
of Northern European descent. They
identified 20 single nucleotide polymorphisms (SNPs) reaching genomewide significance that mapped to genes
related to bone metabolism in signaling
pathways.2 However, bone structure is
not determined by signaling pathways
alone. Past studies indicate that bone
and muscle are interconnected tissues
and that the mechanical forces of
muscles play a major role in determining
bone quality.3,4
We sought to determine whether
the SNPs identified by Rivadeneira et al
found to be associated with higher bone
density (an element of bone quality)

would be predictive of additional measures of musculoskeletal health such as
skeletal muscle and bone volume in a
population of young, healthy adults.
The study population included 753
college-age subjects (449 female; 304
male; average age 24 yrs) recruited to
undergo a 12-week strength-training
program. Measurements of upper arm
muscle volume, strength, and cortical
bone volume were collected prior to
and following resistance training. The
cohort was genotyped for three SNPs
(rs1366594, rs2941740, rs87938) demonstrated to be associated with fracture
risk in genome-wide association studies.
Hardy-Weinberg equilibrium was tested
in each SNP using a chi-square test.
Associations between mean phenotypes
Continued on p. 16

15

Baseline whole muscle volume in Caucasian Females

Baseline whole muscle volume in Caucasian Males
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FIGURE:

for rs87938 demonstrated significantly
larger pre-exercise upper-arm skeletal
and genotypes were tested using an
muscle volume compared to males with
ANCOVA with age and baseline weight
two copies of the rare G allele (p=0.008).
as covariates (cortical bone adjusted for
No significant association was found for
age only). For those associations showing
the rs1366594 SNP in males or females
for the measured
phenotypes.
Although moderate-to-vigorous physical
Our data suggest that SNPs preactivity has been reported to be associated with
viously shown to
be associated with
a hip fracture risk reduction of 45 percent
BMD/fracture
in men and 38 percent in women, the exact
risk (rs2941740
and rs87938) are
contribution of physical activity and muscle
a l s o a s s o c i ate d
with upper arm
strength on BMD and fracture risk remains
muscle volume.
5
These findings are
poorly delineated.
consistent w it h
the mechanostat
a signif icant F-test, pair-wise post
hypothesis, which posits that there
hoc comparisons were performed and
should be a close relationship between
resulting p-values adjusted for multiple
bone strength (or weakness) and muscle
comparisons using the Sidak method.
size/force. According to the mechanostat
Our results demonstrated that
hypothesis, healthy bones dynamically
females that were homozygous for the
adapt to skeletal loads, the majority
recessive allele (n=46) for the rs2941740
of which come from muscular forces.
SNP demonstrated significantly larger
Although moderate-to-vigorous physical
pre-exercise upper-arm skeletal muscle
activity has been reported to be associvolume compared to females heteroated with a hip fracture risk reduction
zygous for that SNP (p=0.026). Males
of 45 percent in men and 38 percent
with two copies of the dominant A allele
in women, the exact contribution of
Continued from p. 15
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physical activity and muscle strength on
BMD and fracture risk remains poorly
delineated.5 Further study of the interplay of genetic influences on bone and
muscle health may lead to a more robust
ability to predict fracture risk.
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Genetic Variation in NADSYN1 (rs12785878) Predicts
Skeletal Muscle Response to Resistance Training and Vitamin D Levels in Men

TRANSLATIONAL

in response to resistance training.
were compared among genot ypes
Our cohort included 753 college-aged
using ANCOVA with age and baseline
subjects (449 female, 304 male) who
weight as covariates (bone phenotype
underwent 12 weeks of supervised
adjusted for age only). For co-dominant
resistance training on
the nondominant arm.
The identification of genetic variants that
At the beginning and
upon completion of
influence vitamin D homeostasis may lead
the exercise protocol,
arm muscle volume was
to early detection of individuals at risk for
measured via MRI and
strength measurements
vitamin D deficiency.
(one repetition ma x
[1R M] and ma ximal
voluntary contraction [MVC]) were
associations showing a signif icant
taken. The study participants were
F-test, pair-wise post-hoc comparisons
genotyped for four genetic variants
were performed and resulting p-values
(rs2282679, rs2060793, rs12785878,
adjusted for multiple comparisons using
and rs3829251) previously demonstrated
the Sidak method.
to be associated with circulating levels of
Our goal was to determine whether
vitamin D in a cohort of 4501 persons of
European ancestry.3,4 Mean phenotypes
Continued on p. 18

FIGURE 1: Significant associations of the rs12785878 genotype and percent change in MVC strength in
Caucasian males.

Baseline whole muscle volume in Caucasian Males

21.8
20.8
Mean % change in MVC strength (lbs.)

Adequate vitamin
D levels are
essential for bone
health and muscle
f unction a nd
therefore physical
performance.1
Low circulating
Sreya Talasila, MSIII
levels of vitamin
Advisors: Laura Tosi, M.D.,
and Joseph Devaney,
D have been
Ph.D. Research Center for
correlated with
Genetic Medicine,
fracture risk
2
Children’s National
a n d f r a i l t y.
Medical Center
Recent genome
wide association
studies (GWAS) have identified single
nucleotide polymorphisms (SNPs) in the
vitamin D binding protein that influence
circulating levels of vitamin D and might
be correlated with deficient states.3,4
Identification of genetic variants that
influence vitamin D homeostasis may
lead to early identification of individuals
at risk for vitamin D deficiency.
The goal of this study was to further
delineate the influence of four loci [GC
(rs2282679), CYP2R1 (rs2060793), and
NADSYN1 (rs12785878, rs3829251)]
that have been strongly associated with
circulating vitamin D levels. We strove
to explore whether these loci might
influence changes in skeletal muscle as a
result of resistance training. NADSYN1
is a novel locus for association with
vitamin D status. There is evidence that
CYP2R1 is a key enzyme underlying
25-hydroxylation of vitamin D in the
liver, and so is a crucial first step in
vitamin D metabolism. GC encodes
vitamin D binding protein and is
strongly associated with circulating
concentrations, which affects the
delivery of circulating vitamin D.3,4
The population used for this study
was derived from a large multicenter
study (FMS) designed to identify genetic
variants that influence muscle size and
strength and individual variability

p = 0.0075
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Mean difference in whole muscle volume (mm3)

SNPs that have exhibited an association
with circulating vitamin D levels are
also associated with skeletal muscle
size and strength, and their response
to resistance training. We found that
males with two copies of the common
allele for rs12785878 demonstrated a
significantly larger increase in skeletal
muscle volume (p=0.035) with resistance
training and a greater percent change
in MVC (p=0.026). No associations
with any of our measured phenotypes
were demonstrated with the other three
SNPs.
Our results demonstrate that certain
SNPs that are associated with higher
levels of circulating vitamin D are also
associated with changes in skeletal
muscle size and strength in males. We
found that males in the FMS cohort
with the common allele of rs12785878
demonstrated a significantly greater
increase in skeletal muscle strength
following resistance training. This
SNP is located in the promoter of
the DHCR7 gene that encodes the
enzyme 7-dehydrocholesterol (7-DHC)
reductase. This enzyme converts 7-DHC
to cholesterol, thereby removing the
substrate from the synthetic pathway
of v it a m i n D3, a pre c u r s or of
25-hydroxyvitamin D3.4 The effect of
this enzyme on vitamin D status requires
further investigation. Our results suggest
novel roles for this gene and potential

85,000

p = 0.0354

75,000

65,000

GT/GG

TT

NADSYN1 (rs12785878) Genotype

FIGURE 2: Significant associations of the rs12785878 genotype and difference in whole muscle volume in
Caucasian males.

directions for future research. The
identification of genetic variants that
influence vitamin D homeostasis may
lead to early detection of individuals at
risk for vitamin D deficiency. This may
lead to early screening and subsequent
prevention of various bone diseases such
as osteoporosis and fractures in males.
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mineral density loci identified by large-scale
meta-analysis of genome-wide association
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determinants of vitamin D insufficiency:
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Clinical
Treatment of Kyphoscoliosis in Proteus Syndrome: Case Report and Review
Proteus syndrome
(PS) is a rare disorder involving a
hamartomatous
overgrowth with
le s s t h a n 10 0
confirmed cases.1
Mark Anderson, MSII
Bone and conAdvisors: Laurel C.
nective tissue are
Blakemore, M.D.,
the most common
Children’s National
tissue types that
Medical Center
u nd e r g o ove rgrowth in Proteus
syndrome with local gigantism, hemihypertrophy, exostoses, macrodactyly, skull anomalies, limb-length
discrepancy, kyphosis, and scoliosis
constituting common manifestations,
orthopaedic management is crucial.1,2
There are only six reports in the orthopedic literature that deal directly with
treatment of scoliosis or kyphosis in PS.
This limited literature has demonstrated
difficulty in attaining lasting curve stabilization, unpredictable tissue reactions
to surgery, and complicating blood loss
and thromboses.2–5
Here, we present a case of severe
kyphoscoliosis associated with PS in
order to address the safety and efficacy of
surgically correcting a spinal deformity
in PS. A male patient was followed
from the age of eleven to the age of
fifteen and received surgical treatment
for progression of severe kyphoscoliosis
associated with PS with posterior spinal
instrumentation and fusion, a process
in which the joints of the spine are
removed, rods are fixed to the spine,
bone graft is placed, and the spine heals
as one solid fusion mass so that curved
growth is arrested.
Our patient was satisfactorily corrected from scoliotic curves of 65o to
17oat C6-T5, 88o to 39o at T5-T10, 41oto
20o at T10-L4, and from a kyphotic
curve of 92 o to 65o at T3-T10 with

CLINICAL

no complications and his correction
remains stable one-year post-operatively
(Figure).
To our knowledge, this is the first
reported case of current deformity
correction strategies employing spinal
osteotomies, thoracic pedicle screws, and
vertebral de-rotation for the correction
of t he k y phoscoliosis a ssociated
with PS. This strategy is contrasted
with the unsuccessful correction in
previously reported cases, which may
be attributable to their employment
of second generation instrumentation

using hooks, wires, or limited screw
fixation. Conflicting recommendations
have been given as to when surgical
stabilization of spinal deformity in PS is
warranted, but since the intelligence and
life span of PS patients are normal, since
spinal deformity may cause secondary
restrictive pulmonary disease, and
since severe kyphoscoliosis can cause
neurological compromise, early surgical
correction of kyphoscoliosis may be
indicated.
Continued on p. 20

FIGURE: Comparison of Pre-Operative and One-Year Post-Operative Radiographs
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Continued from p. 19
This case report is, by no means,
a definitive statement on the safety
or efficacy of surgically correcting
kyphoscoliosis in PS. However, the fact
that our patient’s spinal deformity was
effectively corrected without thrombotic
complication a nd wit hout cur ve
recurrence one year post-operatively
shows that safe and effective correction
is possible. Future studies could aim to

more thoroughly examine the outcome
of current orthopaedic strategies in
correction of spinal deformity in PS
patients.

3. Demetriades D, Hager J, Nikolaides N,
Malamitsi-Puchner A, Bartsocas CS. (1992).
Proteus syndrome: musculoskeletal manifestations and management: a report of two cases. J
Pediat Orthop. 12(1):106–13.
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Extreme Variations in Post-Adenotonsillectomy
Admission Practices in 24 Pediatric Hospitals
Adenotonsillectomy, the surgical removal of
a patient’s tonsils
and adenoids, is
one of the most
commonly perSamita Goyal, MSIV,
for me d proc eAdvisor: David Roberson,
dures in children
M.D., Children’s Hospital
i n t he Un ite d
Boston; and Harvard
States. There are
Medical School
no current guidelines to determine
whether a patient should be admitted for
inpatient observation after undergoing
adenotonsillectomy, leaving much room
for physician and hospital variation.
Concern for postoperative complications may be an impetus for the decision
to admit a patient after adenotonsillectomy. It is well known that children
with obstructive sleep apnea (OSA) are
at greater risk of postoperative airway
collapse, respiratory depression, and
hypoxemia than patients without the
diagnosis.1, 2, 3 This tendency can be
exacerbated by the use of opioids for
peri- and post-operative pain, particularly in the minority of children who
metabolize codeine via an alternate
pathway and may accumulate excess
active metabolite in the bloodstream.1, 4
The objectives of this retrospective analysis were to 1) determine the
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average percent of adenotonsillectomy
patients admitted based on their age
and presence of OSA or other “flagged”
comorbidities (complex chronic conditions such as cystic fibrosis, congenital
abnormalities, etc). across 24 pediatric
hospitals in the country, and 2) to
identify practice variations if they exist
amongst these group, using data from
the Pediatric Health Information System
(PHIS) collected over a one-year period.
Analysis of children undergoing
adenotonsillectomy in twenty-four
pediatric hospitals from July 2009 to
June 2010 was conducted using PHIS.
Patient characteristics were compared
with hospital length of stay. Patients that
were admitted overnight (defined as a
length of stay > 1 day) were classified as
inpatient cases. Children were divided
into four groups based on age (0-2
years, 2–3 years, 3-5 years, and greater
than 5 years) and presence/absence of
comorbidities (+/- OSA, +/- “flags”) and
inpatient admission rates were compared
and contrasted. (Table)
Across all hospitals, younger patients
(0-2 years of age) are more regularly
admitted as inpatient (86.7 percent
inpatient admission rate) than all other
age groups. In addition, patients with
OSA are more likely to be admitted
than their age-equivalent counterparts
without obstructive sleep apnea, as are

5. Yazar T, Cebesoy O, Basarir K, Karadeniz
E. (2005). Recalcitrant scoliosis in Proteus
syndrome. Acta Orthop Belg. 71(3):372–4.

patients who are flagged with a clinical
diagnosis of a complex chronic condition. Across all age groups, 46.9 percent
of patients with OSA were admitted,
while 21.6 percent of patients without
OSA were admitted. Similarly, 68.7
percent of patients with PHIS “flags”
were admitted, while only 28.8 percent
of patients without these “flags” were
admitted. (Table)
As the burden of health care costs
rises, physicians must consider how they
allocate hospital resources. It is unwarranted to admit every patient undergoing adenotonsillectomy, but it is crucial to avoid postoperative complications
in high-risk patients. This data clearly
shows that physicians are aware of the
increased risk in certain patient population groups, reflected by their increased
inpatient admission rates. These high
risk groups include: age under two
years, diagnosis of OSA, and diagnosis
of a “flagged” comorbidity. However,
although this data demonstrates clear
trends for increased admission rates
in certain groups, there is substantial
practice variation. In patients that are
not at high risk for surgery, such as a fiveyear-old patient without any comorbid
diagnosis, the practice variation is even
more significant.
It is our hope that this study, along
with future ones, will help to establish
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concrete guidelines for inpatient admission of pediatric adenotonsillectomy,
for patients with and without comorbid
conditions.
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ALL PATIENTS
		
– OSA
		
+ OSA
		
- Flags
		
+ Flags
		
- OSA/ - Flags
		
- OSA/ + Flags
		
+ OSA/ - Flags
		
+ OSA/ + Flags
		

All age groups
(n=29918)
31.1
(n=29918)
21.6
(n=22665))
46.9
(n=7253)
28.8
(n=28143)
68.7
(n=1775)
37.6
(n=5282)
64.7
(n=649)
53.0
(n=2834)
82.5
(n=570)

0–2 Years
(n=895)
86.7
(n=895)
85.7
(n=539)
88.2
(n=356)
84.9
(n=717)
93.8
(n=178)
84.2
(n=378)
93.3
(n=84)
86.2
(n=231)
94.3
(n=83)

2–3 Years
(n=3277
69.3
(n=3277)
68.6
(n=2273)
70.9
(n=1004)
67.9
(n=3019)
85.7
(n=258)
67.2
(n=1428)
87.9
(n=131)
69.5
(n=622)
82.6
(n=90)

3–5 Years
(n=8370)
33.7
(n=8370)
29.0
(n=6155)
46.7
(n=2215)
31.5
(n=7875)
69.3
(n=495)
27.5
(n=1607)
58.0
(n=181)
42.9
(n=872)
88.5
(n=162)

Older than 5 Yrs
(n=17376)
19.9
(n=17376)
15.5
(n=13698)
36.5
(n=3678)
18.0
(n=16532)
57.8
(n=844)
14.2
(n=1869)
48.0
(n=253)
33.0
(n=1109)
74.1
(n=235)

OSA = Obstructive Sleep Apnea, Flags = presence of at least one comorbidity flag

TABLE: Percentage of children in selected age and clinical groups admitted after adenotonsillectomy

Prospective Blinded Laboratory Assessment of Prophylactic
Antibiotic Compliance in a Pediatric Outpatient Setting
T he A meric a n
Urology
Association
guidelines
suggest that
pediatric patients
diagnosed with
vesicouretal reflux
Neal Patel, MSII
Advisors: Michael
(VUR) be placed
DiSandro, M.D. and
on c ont inuou s
Jenny Yiee, M.D., UCSF
antibiotic
Pediatric Urology
prophylaxis
(C A P) i n a n
attempt to prevent
ascending urinary tract infections
(UTI) that can lead to renal scarring.1
While CAP is commonly prescribed in
ambulatory care settings to impede the
development of UTIs, it is important
to note that patient compliance to
recommended regimens remains to be
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a perpetual issue. Compliance rates
for patients diagnosed with VUR and
prescribed prophylaxis were shown
to be as low as 40 percent.2 Although
compliance has been well studied in
pediatric patients, prior studies for
UTI prophylaxis have focused on
using indirect methods such parental
questionnaires and pharmacy claims
data. The establishment of compliance
by methods such as urine test analysis
can allow for a more concrete perception
of true compliance as subjective
measurements tend to be inflated.3
To our knowledge we conducted the
first prospective, single blinded study
that objectively assessed compliance
by measuring urine antibiotic levels in
children being prophylactically treated
for VUR. Children aged 0-18 years
taking trimethoprim prophylaxis were

recruited to take part in the study.
The subjects were previously unaware
of the study and approached to be
enrolled during follow-up appointments.
Urine samples were collected and sent
to a commercial lab (NMS Labs) to
determine the antibiotic levels. Of
those approached, 97 percent consented
to participate (n=54). Recruitment of
eligible patients was prematurely ended
because preliminary analysis of the
data revealed very high compliance.
The adherence rate was found to
be 91 percent. Age, sex, self-report
of compliance, duration of time on
antibiotics, insurance status, history of
breakthrough infection, surgery, history
of pyelonephritis and hospitalization
were not associated with compliance.
Continued on p. 22
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Continued from p. 21
Our compliance rate of 91 percent
contradicts much of the reported values
for the treatment of UTIs in the pediatric
population and prophylaxis compliance,
which is generally notoriously poor.4,5
The referral of patients with VUR by
a primary care provider to a pediatric
urologist might facilitate compliance
because the seriousness of the condition becomes more apparent, especially
as it made clear that poor compliance
will likely result in the need of surgery.
Furthermore, a specialist can focus on a
single issue for the duration of the entire

visit to ensure that better parental clarity
and understanding is achieved as compared to a primary care setting where
multiple issues demand attention. Future
studies should measure compliance in
both other sub-specialty and general
pediatric clinics. If proper compliance for
prophylactic treatment is not established,
perhaps pediatric urologist should be
more involved with the care regardless
of the future likelihood of surgery.
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Prevalence and Treatment of Methicillin-Resistant Staphylococcus Aureus (MRSA)
in Hand Infections Presenting to an Urban Setting
The prevalence
of Methicillinresistant
Staphylococcus
Aureus (MRSA)
infection is
increasing in
the hospital setRishi Sood, MSII
ting.1 The rise of
Advisor: Joseph R.
antibiotic resisO’Brien, M.D., GW School
tant pathogens
of Medicine and Health
continues in the
Sciences
modern American
hospital despite
evolving hygienic practices. As a major
concern to all surgeons, proper prophylactic treatments can help reduce the
rate of new MRSA infections and mortality. The National Surgical Infection
Prevention Project (NSIPP) uses guidelines published in 1993, which state that
cefazolin or cefuroxime are sufficient
for surgery prophylaxis. The same
report also indicates that vancomycin
or clindamycin only be considered if
the patient has a beta-lactam allergy.
The NSIPP states that for best results,
prophylaxis be started at least 60 minutes before operations and be continued
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Antibiotic
Cefazolin
Clindamycin

Cases susceptible (%)
0 (0%)
38 (92.7%)

Cases resistant (%)
41 (100%)
3 (7.3%)

Vancomycin
Tetracycline
Oxacillin

41 (100%)
35 (85.4%)
0 (0%)

0 (0%)
6 (14.6%)
41 (100%)

Gentamycin

41 (100%)

0 (0%)

Rifampin

41 (100%)

0 (0%)

TABLE: Antibiotic Resistance and Susceptibility to MRSA.
for only 24 hours after completion.2
Although cefazolin continues to remain
the mainstay for prevention of wound
infection, our study indicates that it is
ineffective against MRSA. This study
aims to demonstrate that clindamycin
or vancomycin should become the preferred treatment in the prevention of
MRSA infections.
We retrospectively evaluated 82
patients who presented with hand
infections to Washington Hospital
Center from the years 2003–09; these
patients were then operated upon. The
specimens obtained during the initial
evaluation and treatment were cultured

and subjected to antibiotic susceptibility
testing (Table). Only patients who
had cultures positive for MRSA were
selected for relevant data analysis. The
following antibiotics were selected
for testing susceptibility to MRSA:
cefazolin, clindamycin, vancomycin,
tetracycline, oxacillin, gentamycin, and
rifampin. All information, including
patient demographics, was obtained
from patient charts.
Forty one of 82 (50 percent) patients
had cultures testing positive for MRSA.
Cefazolin and oxacillin had no effect
in preventing or treating MRSA as all
positive cultures (n=4) showed bacterial
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resistance. Vancomycin, gentamycin,
and rifampin were effective in all cases
(n=41). Clindamycin was not resistant in
92.7 percent (n=38) of MRSA cultures.
Tetracycline demonstrated efficacy in
treating 85.4 percent (n=35) of MRSA
cultures.
The choice of empiric antibiotic is
becoming increasingly difficult since
cefazolin has long been favored despite
its ineffectiveness in preventing MRSA.3
The CDC has not yet published
guidelines for MRSA prophylaxis during
surgical procedures. Surgeons must
rely on institutional guidelines or the
National Surgical Infection Prevention
Project’s (NSIPP) recommendation,
which cites a paper published in 1993.
Given that these guidelines were
published almost two decades ago,
newer and more effective antibiotics

should be considered for surgical wound
prophylaxis.
The rate of community acquired
MRSA hand infections in an urban
setting is higher than previously suspected and the rate of MRSA positive
cultures in our sample group is 50
percent (n=82). Resistance to cefazolin
and oxacillin was found in all cultures
whereas vancomycin, gentamycin, and
rifampin demonstrated no resistance.
Clindamycin and tetracycline had substantially more efficacy than cefazolin or
oxacillin with MRSA susceptibility rates
at 92.7 percent and 85.4 percent respectively. Although our patient sampling
was relatively small, our subjects were
good indicators of the general population presenting to an urban hospital.
This data should be taken into account
when managing seemingly routine

hand infections given that the treatment options are different for MRSA
infections. Specifically, based on our
findings, cefazolin and oxacillin should
be avoided as empiric antibiotics in favor
of vancomycin, gentamycin, rifampin
or clindamycin and tetracycline when
preventing potential MRSA infections.
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Corpus Callosum DTI Measurements in Neurofibromatosis Type I and Normal Controls
Neurofibromatosis type
1 ( N F-1) i s a
common inherited disorder with
a prevalence of
approximately
A m i r N o o r, M S I I
1 in 2500-3000
Advisor: Nadja Kadom,
births. The disMD, Children’s National
ease affects the
Medical Center
bra in in ma ny
ways, including
structural abnormalities, such as macrocephaly and enlargement of the corpus
callosum. The presence of cognitive
deficits in NF-1 patients has lead to
numerous investigations trying to find
correlations between structural brain
abnormalities and cognitive dysfunctions. Several studies have linked cognitive deficiencies in NF-1 patients to
enlargement of the corpus callosum.1,2
The pathophysiological basis of
corpus callosum enlargement (CCE)
is not well understood. Four leading
hypotheses to explain CCE have been
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Averaged Two Observers
Skull (mm^2)
CC-Skull Ratio
Radial Diffusivity
Axial Diffusivity
Apparent Diffusion
Coefficient (ADC)
Fractional Anisotropy

NF-1
15326
0.04900
0.00040
0.00140
0.00078

Controls
14344
0.03894
0.00037
0.00148
0.00098

P-value
0.0001
0.0001
0.023
0.0002
0.067

0.71711

0.74969

0.0012

TABLE: Averaged data of several measurements used to compare NF-1 patients to matched control patients
without NF-1.

proposed: 1) increased number of
commissural fibers due to reduction
in apoptosis; 2) excessive myelination
resulting in larger axons; 3) increased
extracellular fluid, and 4) myelinopathy
associated with vacuolation, or a combination of all four of these factors.3
Imaging parameters, such as diffusion
tensor imaging (DTI) have been used
in adults to further evaluate structural
features of CCE in adult NF-1 patients.3
DTI measures, such as mean diffusivity

(MD), fractional anisotropy (FA), axial
and radial diffusivity, allow for indirect
assumptions regarding brain structure.
MD reflects the size of the interstitial
space that allows for overall molecular
diffusion. FA relates to the directionality
of diffusion that is mainly affected by the
architecture of the environment around
the interstitial space. Axial diffusivity
(AD) represents the dominant direction
Continued on p. 24
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of diffusion along the long axis of fibers.
Radial diffusivity (RD) ref lects the
average diffusion of directions perpendicular o long axis. The goal of our study
was to investigate the pathophysiological
basis of corpus callosum enlargement
in NF-1 patients through these DTI
measurements.
Patients were consecutively selected
from institutional data base with the
inclusion criteria being: having an established diagnosis of NF-1, brain imaging
with DTI sequence, abnormally high
corpus callosum to skull ratio. Patients
with complications of NF-1 that could
affect size of the corpus callosum were
not included in this study. Subjects were
age and gender matched with normal
controls that were randomly selected
from the radiology database. Manual
regions of interest (ROI) were placed
over the corpus callosum for DTI measurements using DTI-Studio by two
independent researchers, one blinded
to diagnosis. Fifteen NF-1 patients
and matched controls were analyzed.
The corpus callosum to skull ratio
was found to be significantly different

between the experimental and control
future studies we will correlate abnormal
group (p=0.0001). For NF-1 patients
corpus callosum DTI markers with cogwe found: a trend to lower apparent
nitive functions in NF-1 patients to see
diffusion coefficient (ADC, p=0.067),
if relationships exist that can be used as
significantly higher radial diffusivity
predictors of cognitive deficits in young
(p=0.023), significantly lower axial
NF-1 patient.
diffusivity (p=0.0002),
and significantly lower
The trend of lower ADC may indicate low
fractional anisotropy (FA,
p=0.0012).
axonal diameter, as ADC has been shown
T he sig n i f ic a nt ly
lower axial diffusivity
to more strongly correlate with axonal
in NF-1 patients can
diameter without the myelin sheath.
indicate that there are
more crossing fibers in
the corpus callosum of in
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Idiopathic Transverse Myelitis and Arteriovenous Malformations:
A Chart Review of 94 Patients for More Efficient Diagnoses
Idiopathic transv e r s e my e l it i s
(ITM) is a clinic a l s y nd rome
caused by a focal
inflammation of
the spinal cord
Jasmine Dukandar, MSII
c au sing demyAdvisor: Michael Levy,
elination a nd
1
M.D., Johns Hopkins
necrosis. Spinal
Hospital
cord arteriovenous malformations (AVMs) are shunts fed by arteries
normally supplying the neural tissue.2
ITM and spinal cord AVMs present
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similarly in a clinical setting. Sensory
changes in legs and some form of bowel
or bladder dysfunction are common
clinical characterizations. The similarity
in presentation of these conditions poses
a problem for quick and effective treatment due to their different etiologies.
When an AVM is detected, treatment
is aimed at halting the progression of
the disease.2 Diagnosis usually rests on
a positive CT angiography test in spinal
cord AVMs. In addition, there is a slight
variance in sensory level, defined as the
most caudal level at which sensation
is intact. For ITM the most common

sensory level in adults is the midthoracic
region.3 Most arteriovenous malformations result in a thoracolumbar sensory
level.4 For AVMs, prognosis depends
on the extent of ischemia and necrotizing myelopathy present at the time of
diagnosis, indicating the importance of
the timely recognition of disease.5 The
delay in performing CT angiography to
rule out AVMs and lack of knowledge
of differentiating signs on presentation
give cause for evaluation.
A retrospective review was performed
of 94 cases of myelopathy referred for
angiogram, comparing subjects whose
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final diagnosis was ITM versus AVM.
The aim was to assess any differences
between ITM and AVM to provide
more efficient diagnoses in the future.
Gender demographics of the examined
94 patients with ITM and AVMs were
relatively equal, with 55 percent males
and 45 percent females. Substantially
more males (76 percent) were affected
by AVMs in our patient population
compared to females (24 percent).
In terms of clinical characterization
based on physical examination, ITM
and AVM patients were found to have
slightly impaired functioning in lower
extremities in strength tests, while their
upper extremities appeared unaffected.
80 percent of all patients were found
to have sensory changes in their lower
extremities, while just 7 percent were
found to have sensory changes in their
upper extremities. 75 percent of ITM
and 59 percent of AVM patients experienced bladder or bowel dysfunction.
As expected, the majority (60 percent)

of ITM patients had an acute onset
of disease, while 65 percent of AVM
patients had a progressive onset. In
terms of response to treatment, it was
found that 55 percent of ITM patients
showed improvement with steroids,
while only 19 percent of AVM patients
showed improvement. Also, 59 percent
of AVM patients were found to have a
vascular risk factor such as hypercholesterolemia, hypertension, or diabetes
mellitus, in comparison to 45 percent
of ITM patients.
These data demonstrate that while
characterizing the clinical differences
between ITM and AVMs still remains
somewhat clinically ambiguous, there
are clinical markers that can lead to a
more timely diagnosis. While a positive spinal angiogram still remains the
most accurate way of distinguishing an
AVM, a lack of response to steroids also
likely indicates that vascular etiology in
the spine may be involved. A thorough
patient history including onset of the

disease, acute versus progressive, may
prove to be more indicative of a particular diagnosis. Additional evaluation of
the importance that risk factors such as
hypercholesterolemia, hypertension, and
diabetes mellitus play in AVMs may also
lead to a more efficient diagnosis and
therefore better prognosis for patients.
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Familial Aggregation of Panic Disturbances in Parkinson’s Disease
Pa nic d isorder
is one of t he
mo s t c om mon
anxiety disorders
i n Pa rk i n son’s
d i se a se ( PD)
with a prevalence
Justin Palanci, MSI
of 10 percent-30
Advisor: Gregory Pontone,
p e rc e nt .1 I n
M.D., Johns Hopkins
addition, there is
University
a high prevalence
of atypical ‘paniclike’ anxiety disturbances correlated with
motor and antiparkinsonian medication
fluctuations in PD.2 One previous study
reported distinct demographic and
clinical features in individuals with PD
and panic disorder as compared to PD
subjects without anxiety, suggesting
that panic disorder may be uniquely
associated with PD and useful as a
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marker associated with disease etiology
or prognosis.3 To investigate the validity
and significance of panic disorder as a
phenotypic subtype in PD, this family
study investigated the heritability
of panic disorder and ‘panic-like’
symptoms in PD.
Pa rticipa nts were adu lts wit h
idiopathic PD and their first-degree
relatives. They were recruited from
movement disorder practices in the
greater Baltimore area. Panic disorder
status was determined by a psychiatrist
as part of a comprehensive psychiatric
evaluation. Case probands with PD
and panic disorder (PD-PANIC, n=20)
and a comparison group of non-anxious
PD probands (PD-NA, n=17), defined
as having no history of any anxiety
disorder, no current mood disorder
or major psychotic disorder, were

identified. The sample included 222
first-degree relatives (114 PD-PANIC
relatives and 108 PD-NA relatives).
Evaluations to determine panic
status in relatives were conducted by
phone. When relatives were deceased,
unreachable, or unwilling to participate;
informant ‘proxy’ interviews were
conducted by interviewing another
family member or spouse.
Demographic and clinical variables
in PD-PANIC and PD-NA probands
were compared using t-tests and the
chi-square statistic. Significance was set
a priori at p < 0.05. The odds of panic
disorder and ‘panic-like’ phenomena
in first-degree relatives were estimated
using logistic regression by the method
of generalized estimating equations,
Continued on p. 26
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which accounts for within-family
correlation among relatives.4
Table 1 shows the demographic
and clinical features of the PD-PANIC
and PD-NA probands. As compared
to the PD-NA probands, PD-PANIC
probands were significantly younger
(p=0.001), had a longer duration of PD
(p=0.04), higher L-dopa doses (p=0.02),
and greater ADL disability when in the
‘off’ state (p=0.03). However, they had
comparable PD severity as measured
by the Hoehn and Yahr stage and the
UPDRS Motor sub-score.
As shown in Table 2, the prevalence
and odds of panic disorder and ‘paniclike’ disorder is greater for relatives of
PD-PANIC probands when compared
to PD-NA probands [OR=16.13,
p=0.01]. Regression analyses showed
that the significant group differences
in prevalence rate persisted after
controlling for potentially confounding
variables: younger age of PD-PANIC
probands, presence of current depressive
disorder in probands, higher prevalence
of panic phenotype in female relatives,
and higher prevalence of the panic
phenotype in directly interviewed
relatives.
The finding that panic disorder and
‘panic-like’ disturbances are familial in
PD suggests that they may be genetically
based and not simply accounted for
by exposure to dopaminergic therapy
or a reaction to motor impairment.
The similarities between PD-PANIC
probands and a previously described
subgroup of ‘younger-onset’ PD patients
suggests that panic-type anxiety may be
an additional clinical marker for earlier
onset PD and possibly an endophenotypic
feature that co-segregates with relatives
at increased risk for this PD variant.5
Given the implications of these findings
and the high prevalence of panic
disorder in patients with PD, routine
screening for panic phenomena in
patients with PD should be considered.
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Characteristic
		
Sex, No. (%)
		Male
		Female
Current age, years
Education, years
MMSE Total
Age at PD Symptom Onset, years
Age at PD Diagnosis, years
PD Symptom Duration, years
Cumulative LDOPA Use, mg
Agonist Use, No. (%)
Hoehn & Yahr Stage Score
Motor Fluctuations, No. (%)
UPDRS Sub-scores
		 I (Mentation, Mood)
		 II (ADL) Off
		 II (ADL) On
		 III (motor)
		 IV (Therapy complications)

PD-PANIC Probands
(n=20)

PD-NA Probands
(n=17)

P

11(55)
9(45)
61.2(7.6)
16 (3)
28.7(1)
49.1(9.3)
50.6(9.4)
12.1(7.4)
815.1(587.7), n=18
4(22), n=18
2.3(0.9)
11(73),n=15

11(65)
6(35)
70.8(8.4)
17(3)
28.8(1.3)
63.9(12.5)
64.7(12.4)
6.9(6.9)
442.4(205.1)
8(47)
2(0.9)
3(18)

0.55

3.9 (3), n=18
15.3(7.6), n=18
13.1(8), n=16
20.3(9.8), n=18
5.3(3.3), n=18

1.1(1.1)
10.2(5.8)
9.8(5)
15.4(9.6)
2.2(3.8)

0.001
0.03
0.15
0.16
0.02

0.001
0.32
0.76
0.0002
0.001
0.04
0.02
0.12
0.12
0.002

Mean (SD): UPDRS – Unified Parkinson’s Disease Scale; ADL – Activities of Daily Living

TABLE 1: Demographic and Clinical Features of PD-PANIC and PD-NA Probands
Characteristic of Relative

Odds Ratio (95% CI)

P

16.13 (1.82–142.7)
1.0

0.01

		Female
		Male

4.08 (1.25–13.3)
1.0

0.02

Type of Interview
		Direct
		Proxy

3.14 (0.96–10.3)
1.0

0.06

Odds Ratio (95% CI)

P

0.984 (0.91–1.05)

0.55

1.08 (0..35–3..27)
1.0

0.90

Group
		Case
		Control
Sex

Characteristic of Proband
Proband age
		PD-PANIC
		PD-NA1.0
Proband Depression Status
		 Current Depression
		No Depression

TABLE 2: Adjusted Odds Ratios for Panic Disorder and “Panic-like” Disturbances
Fusion ✦ 2012
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Perceptions of Glycemic Control and Frequency of Type 2
Diabetes Fundus Photography
T he A meric a n
Diabetes
Association recommends annual
fundus examination services for
all t ype 2 diaAndrew A. Yaeger, MSI
betes patients.1
Advisor: Stanley C.
However, not all
Patterson, M.D., Magnolia
patients, espeClinic – Ventura County
cially minorit y
Medical Center
patients, receive
t e s t i n g on a n
annual basis.2 Factors such as cost of
service, time spent in the referral process, misinformation about the disease
process, young age, and poor glycemic
control prevent patients from receiving
eye care.3 Fundus photography has been
proposed as a follow-up diagnostic tool
to annual fundus examination, given
their comparable efficacy.4 Fundus
photography was studied as opposed to
dilated eye examination by a specialist, as
the cost of service and referral wait-time
is less of a burden for our underserved
population. This study was designed to
identify patient factors that contributed
to a low rate of screening among our type
2 diabetes patients. These factors could
be used to flag patients deemed high risk
of not receiving these services.
351 patients were selected randomly
from our photography database. The
patient population most frequently
self-identified as Hispanic (n=265) and
female (n=218). The average age of
patients was 52 ±10 years. Race and sex
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did not associate significantly with any
variable. Patients in the study were asked
to complete a bilingual questionnaire.
Survey responses were grouped into
four main categories for analysis: screen
frequency, years with a diagnosis of type
2 diabetes, retinopathy, and perception
of glycemic control. If a patient selected
a poor or fair response for their glycemic
control, they were grouped into the lower
than moderate group. If the patient
selected a good or excellent response
they were grouped into the better than
moderate group. Electronic medical
records were then used to associate
most recent hemoglobin A1C (HbA1c)
and retinopathy diagnosis at the time of
photography, to the responses.
These categories were then evaluated: The HBA1C level was associated
with the patient responses to provide
an objective measurement of glycemic
control in this population. The responses
consisted of lower than moderate (LTM;
Most Recent HbA1C= 8.7 ± 2.0 percent); moderate responses (Most Recent
HbA1c= 8.44 ± 1.9 percent); and better
than moderate (BTM; Most Recent
HbA1C=7.7 ± 1.9 percent). Data was
analyzed using Fischer’s exact test.
The frequency of receiving fundus
photography was not significantly associated with the number of years diagnosed with type 2 diabetes, nor was it
significantly associated with the patient’s
subjective level of control. The patient’s
perception of control was significantly
associated with years diagnosed with

type 2 diabetes — with patients who
have had type 2 diabetes less than or
equal to 10 years more likely to state
BTM than LTM levels of control. Also,
patient perception is not associated with
a diagnosis of retinopathy. The presence
of retinopathy is not associated with
screen frequency, but is associated with
years diagnosed with type 2 diabetes, as
was expected.
Other studies have shown an association between measured levels of glycemic
control and screen frequency in an established fundus photography program.5
In this study, perception of glycemic
control was not associated with rate of
attendance. For example, those patients
who state LTM levels of control were
not less likely to attend eye screening
services than a patient who states BTM
levels of control. As a result, perceptions
of glycemic control should not be used
to classify patients as high risk of nonattendance in patient populations with
similar demographics. Further research
is needed to determine if other patient
or provider variables, such as underlying
mental illnesses, economic issues, or
provider biases, influence the frequency
of obtaining fundus photography.
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Associations

Fisher Exact P

Continued from p. 27

Odds Ratio

Screen Frequency		
		 Years with T2DM
0.37
		 Subjective Level of Control
0.44

0.76
0.75

Subjective Level of Control		
		 Years with T2DM
0.014*
		 Retinopathy
0.15

0.41
1.62

Retinopathy		
		 Years with T2DM
<0.000001†
		 Screen Frequency
0.32

6.72
0.77

and disease for racial and ethnic minority
populations — a literature review. J Natl Med
Assoc. 101:430–437
3. Hartnett, ME, Key IJ, Loyacano NM, Horswell
RL, DeSalvo KB. (2005). Perceived barriers to
diabetic eye care: qualitative study of patients
and physicians. Arch Ophthalmol. 123:387–391
4. Taylor CR, Merin LM, Salunga AM, Hepworth
JT, Crutcher TD, O’Day DM, Pilon B. (2007).
Improving diabetic retinopathy screening
ratios using telemedicine-based digital retinal
imaging technology. Diabetes Care. 30:574–578
5. Leese GP, Boyle P, Feng Z, Emslie-Smith A,
Ellis JD. (2008). Screening uptake in a wellestablished diabetic retinopathy screening
program. Diabetes Care. 31:2131–2135.

TABLE: Fisher’s exact test testing and odds ratio of responses tested at 95% Confidence. Values with a P<0.05
are considered statistically significant.

Validation of Cardiac Procedure Codes in Canadian
Hospital Administrative Databases
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cardiac procedures in the Canadian
Institute for Health Information (CIHI)
administrative databases, and compare
them with the Cardiac Care Network
(CCN) clinical registry of cardiac
procedures. The CIHI cohort is a
centralized population-based database
that is collected by the hospital’s

administrative staff and contains only
demographic information from all
hospital discharges across Ontario.
The CCN database is very cohort
specific and is collected by trained nurse
abstractors, including only patients
who have undergone cardiac surgery. In
addition to demographic information,
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Cardiovascular diseases (CVD)
are major chronic
conditions with
significant mortality, morbidity
and resource utilization burden.
Jeff Shu-Chieh Yu, MSI
In Canada, CVD
Advisor: Douglas Lee,
has reduced
M.D., Ph.D., Institutes
for Clinical Evaluative
the average life
Sciences, Toronto,
e x pe c t a nc y by
1
Canada
2.8 years. While
c a rd iac proc edures are an effective method routinely
used to treat CVD, they are often
costly and should be closely monitored.
Administrative databases, initially
developed for the purpose of tracking
patient volume and hospital activities,
are potentially powerful tools for cardiac
procedure surveillance due to their representativeness, availability, and capture
of data over many years at relatively low
cost.2 However, they must first be validated against clinical registries in order
to ensure accuracy.
The purpose of this study was to
determine the validity of coding of
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a one day window in terms of procedural dates were included. Further increases resulted in minimal increases in PPV
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the patient’s cardiac history, preexisting
comorbidities and cardiac procedure data
were collected. We hypothesized that
widely used cardiac procedures, including
percutaneous coronary intervention
(PCI), coronary artery bypass graft
(CABG) surgery, valve surgery, and
cardiac catheterization would be
accurately coded in administrative
databases when compared with a clinical
registry.
We e x a m i n e d t h e C I H I
administrative database for all PCIs,
CABG surgeries, cardiac valve surgeries,
and cardiac catheterization procedures
performed at 18 cardiac care centers in
Ontario, Canada between the 2005 and
2006 fiscal years. Cardiac procedures
were matched between the CIHI and the
CCN databases whether they occurred
on the same day in the same patient at
the same hospital site. We determined
the positive predictive value (PPV) of
CIHI coded procedures as the numbers

of matching procedures divided by
total procedure counts in CCN. As the
procedure dates can be a common source
of mismatch, we repeated the analysis
after expanding the allowable window
for matching to ±1 day. To determine
the extent of the time window’s impact,
we expanded the window for matching
to ±7 days in a sensitivity analysis.
The PPV of the administratively
coded CABG surgery from the CIHI
databases was 97 percent. For valve
surgery procedures, the accuracy of
administrative databases was 96 percent. When compared against the CCN
clinical registries, the coding accuracy
of both PCI and cardiac catheterization
were 94 percent. When the procedure
date window was expanded from the
same day to ±1 day, the PPV improved
to 96 percent for PCI and exceeded 98
percent for CABG surgery, 97 percent for
valve surgery, and 95 percent for cardiac
catheterization.

In sensitivity analyses, we expanded
the matching date window to ±7 days
(Figure). The highest increase in PPV
occurred when the date window was
widened by ± 1 day, and there were only
minimal increments in predictive value
thereafter (Figure).
In summary, our evaluation suggests
that administrative coding of CABG
surgery, valve surgery, PCI, and cardiac
catheterization procedures is valid, and
therefore is a better alternative for outcomes research because they are readily
available, cheaper to prepare and at least
as accurate as a province-wide prospective registry.
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Design and Validation of the Aviation Laser Exposure Self-Assessment
L A SER is an
acronym for Light
Amplification
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the eye’s optical
Civil Aviation Authority
system is capable
of focusing radiation, it is particularly vulnerable.1
Reports of aircrafts exposed to lasers are
a growing concern due to the increasing
availability and decreasing price of handheld lasers.2 In the first six months of
2011, there were 671 cases reported to the
Civil Aviation Authority (CAA) of the
United Kingdom. Many countries have
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criminalized directing lasers at aircrafts
and operational procedures to deal with
exposure have been established.3 While
nearly all of the reported exposures
have not been associated with long term
physical damage, the increasing power
of available lasers raises the possibility.
There are currently no guidelines
for a rapid self-assessment to assist in
determining if professional treatment
should be sought after eye illumination
from a laser. Eye damage, particularly
retinal damage, can be painless, and
may result in a delay in medical care.3
Uncertainty can also send individuals
to see a physician unnecessarily. The
Aviation Laser Exposure Self-Assessment
(ALESA) was created as a convenient
means to assist in self-evaluation after a
laser beam incident.
A review of laser incidents reported
to the CAA was conducted. To center

the ALESA on aspects of the incident
that could be easily be identified, wavelength (color) dependent distances for
perceived brightness levels were obtained
and compared to the Nominal Ocular
Hazard Distance (NOHD). An algorithm was created to indicate whether
the experience had exceeded maximum
permissible exposure and therefore
warranted medical examination. A
symptoms list and an Amsler grid were
included to account for visual disturbances and general eye problems. Five
experts in laser study and/or ophthalmology, in addition to a flight operations
inspector, were consulted throughout
the ALESA’s creation.
A five point Likert-type scale was
developed to gauge the attitudes of pilots
and flight crew on the use of the ALESA.
Continued on p. 30
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Continued from p. 29
The study population consisted of 25
male and female pilots and flight crew
members who have experienced aviation
laser beam exposure. Because the participants were considered hard-to-find
types of individuals, network sampling
was used. After completing the ALSEA
based on their most recent exposure,
they indicated their level of agreement
on six dimensions: time saving potential,
likelihood of use, ease of completion,
need, accuracy, and decrease in anxiety.
The proportion agreeing (responding
favorably) was found to be significant
in all aspects of the ALESA except for
its ability to decrease anxiety. Content
validity was established by the expert’s
judgment of the appropriateness of the
ALESA and face validity was found by
the participant’s responses. The ALSEA
was shown to be of use to the aviation
community and the CAA is currently
distributing the tool throughout the
United Kingdom. None of the participants experienced permanent damage
from their exposure and the probability

Stephanie Waggel with the London Metropolitan Police Service Air Support Unit.

of such damage at this time is extremely
low. As the power of lasers purchased by
the public increases in the future, it will
be desirable to establish the sensitivity
and specificity of the ALESA.
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Losses to Follow-up Among Patients Registered
for Care at a Tertiary HIV Referral Center in Chennai, India
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and Antiretroviral Therapy (ART) is
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available in India via the public and
private sectors. While services such as
physician consultation and ART costs in
the government sector are free, patients
are generally required to pay for these
and other services in the private sector.
Unfortunately, it is difficult to ascertain
the efficacy of ART treatment since
there is limited data on loss-to-follow
up (LTFU) rates and factors associated
with LTFU in India.
Our case control analysis comprised
a subset of patients registered for care
at YRGCARE (a private non-governmental organization providing HIV
clinical services in Chennai since 1993)

between Jan. 1, 2004 and Dec. 31, 2009.
Cases (LTFU) were defined as patients
who did not have at least one visit
between Jan. 1, 2010 and Dec. 31, 2010.
“Project” patients included the subset of
patients who were enrolled in clinical
trials or projects and received some
compensation for clinical care (e.g., free
ART, free consultation, compensation
for travel, etc.) and who were assigned
retention staff. Logistic regression was
used to identify factors associated with
LTFU.
Of 7,995 patients included in the
analysis, 68.2 percent were male with
a median age of 34 years. The overall
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Kaplan-Meier Survival Estimate
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loss to follow-up rate was 38.1 per 100
person-years p-y. Among those who were
LTFU, there were 304 (3.8 percent) documented deaths. In univariate analysis,
LTFU was less common in those with
higher baseline CD4 count, higher CD4
count at last visit to the clinic, being
enrolled in a project and having initiated
ART. LTFU was more common among
patients who were older and unmarried.
In multivariate analyses, persons were
significantly less likely to be LTFU if
they were enrolled in a project (OR:
0.66; 95 percent CI: 0.58, 0.77), being
initiated on ART (OR: 0.32, 95 percent
CI: 0.26. 0.38) or married (OR: 0.71, 95
percent CI: 0.57, 0.88).
This clinical cohort exhibited a
high-rate of LTFU as the majority of
the losses occurred within the first
month. Given the negative association of
LTFU with being enrolled in a project,
innovative strategies using incentives
(e.g., conditional cash transfer, travel
incentives) and peer-health workers in
improving retention among patients
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FIGURE: Kaplan-Meier curve of overall dropout fromAnalysis
clinical care

needs to be evaluated for efficacy and
cost-effectiveness, considering that cash
incentives can improve HIV-positive
patient follow-up.1 Given the high rate
of mortality among patients LTFU
compared to documented deaths in
the clinical cohort, the impact of these

deaths on survival analyses need to be
examined.

REFERENCES:
1. Over M. “Sustaining and Leveraging AIDS
Treatment.” Center for Global Development. www.cgdev.org/content/publications/
detail/1424173.

The Rise of Ciprofloxacin-Resistant Urinary E. coli
Among Older U.S. Outpatients, from 2000 to 2010
Ur i n a r y t r a c t
infections (UTIs),
including acute
c ystitis (infection of the lower
u r i n a r y t r a c t)
a nd pyeloneGuillermo Sanchez,
ph r it i s (i n fe cM.P.H./P.A. candidate
t ion i nvolv i ng
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the kidney), are
M.D., Ph.D., Section
among the most
of Infectious Disease,
frequently occurProvidence Hospital
ring infections in
humans.1 Among
non-institutionalized elderly individuals, UTIs are the second most common
type of infection, representing approximately 25 percent of all infections.1
We used data from The Surveillance
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Network (TSN) to describe in vitro E.
coli antimicrobial resistance among
isolates collected from older outpatients
(ages 65 and older) in the United States
from 2000 to 2010. Details of this surveillance system have been described
previously.3 Susceptibility testing is
performed on site by each laboratory in
accordance with FDA-approved testing
methods and interpreted using Clinical
and Laboratory Standards Institute
(CLSI) recommended breakpoints. The
objective of this study was to examine
trends and prevalence of the antimicrobial resistance of urinary E. coli isolates
to commonly prescribed antimicrobial
agents among older outpatients (65+)
in the United States from 2000 to 2010.
Susceptibility testing results from

urinary isolates of E. coli (n = 2,555,999)
were examined from U.S. outpatients
from 2000 to 2010 (see Figure). The
greatest increases in antimicrobial resistance from 2000 to 2010 were observed
for ciprofloxacin 6.0 percent to 29.5
percent and TMP/SMX 16.3 percent
to 26.8 percent, whereas nitrofurantoin
1.5 percent to 2.8 percent demonstrated
a small increase (see Table). In 2010,
ampicillin, amoxicillin-clavulanate, and
tetracycline demonstrated resistance
rates of 45.7 percent, 7.0 percent, and
24.9 percent, respectively.
E. coli antimicrobial resistance
among older U.S. outpatients increased
markedly for ciprofloxacin and TMP/
Continued on p. 32

31

DRUG

Total Isolates
2000–10

2000

2001

2002

IMP/SMX
Ciprofloxacin
Ampicillin
Amox/Clav
Nitrofurantoin
Tetracycline

2,034,254
1,836,598
2,002,221
759,749
1,972,633
580,328

17.9
3
38.2
5
0.8
22.6

17.8
3.7
38.1
4.1
1
22.1

18.1
5
38.2
5.3
1.1
22.1

2003

Percent Resistance
2004 2005 2006

2007

2008

2009

Total Change
2010 2000–10 P-value*

18.2
6.2
38.2
4.5
1.1
21.1

19.4
7.5
38.2
3.7
1
21.9

21.9
14.1
41.5
8.2
1.5
23.7

22.9
16
42.4
9.9
1.5
24.4

23
16.3
42.4
6.6
1.6
24.5

24.2
17.1
43.4
5.3
1.6
24.9

20.2
9.7
39.4
3.8
1.1
22

20.8
12.2
40.5
5.6
1.4
23.5

6.3
14.1
5.2
0.3
0.8
2.3

<0.0001
<0.0001
<0.0001
0.0054
<0.0001
<0.0001

NOTE: Isolates demonstrating intermediate susceptibility were not counted as resistant. Amox/Clav, Amoxicillin/Clavulanate; TMP-SMX, Trimethoprim/Sulfamethoxazole.
Comparison of 2010 vs. 200 antimicrobial resistance rates

TABLE: Annual Rates of Antimocrobial Resistance in Urinary Eschericha coli Isolates to Select Antimibrobials in United States Outpatients, 2000–10.

SMX from 2000 to 2010. Though
rises in resistance have been reported
previously for TMP/SMX, such substantial increases in E. coli resistance
to ciprofloxacin have yet to be reported
among older U.S. outpatients. These
results highlight a disturbing trend of
soaring resistance that will have a profound effect on how UTIs are treated
in the outpatient setting. When resistant uropathogens such as E. coli are
encountered, the likelihood of a clinical
cure decreases and risk of recurrence
increases.3 Additionally, resistance significantly increases patient morbidity,
costs of treatment, rates of hospitalization, and use of broader spectrum
agents.4 As the availability of efficacious
antimicrobial therapies dwindles in the
wake of rising antimicrobial resistance,
the population that will be most severely
affected will be older adults like the ones
represented in this study.
The strengths of this investigation
include the large number of isolates,
the long time period for which data
were collected, and the variety of agents
examined. Although passive surveillance
systems such as TSN are suitable for
examining patterns in antimicrobial
resistance , they are generally not used to
guide therapeutic use of empiric agents.
Local susceptibility data that are collected prospectively through active local
surveillance are more appropriate when
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determining proper empirical therapy
for the treatment of uncomplicated
UTIs among individual patients.
In summary, our study shows that
from 2000 to 2010 E. coli antimicrobial
resistance to ciprofloxacin and TMP/
SMX increased substantially among
older outpatients in the United States,
whereas lower resistance to nitrofurantoin remained low. Given the frequency
with which UTIs are treated empirically,
compounded with the speed that E. coli
acquires resistance, judicious selection
of empirical agents in the outpatient
setting remains crucial.
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Design and Conquer
The serendipity of collaboration, ingenuity, and innovation
have often stemmed from the desire to create something new
from a variety of perspectives and sources of knowledge.
This is exemplified in the medical field and incorporated
in the theme of this year’s edition of Fusion. Inspired by
this integration of research and clinical care, the cover is a
fusion of two different mediums by two second-year medical
students; an anatomical sketch of a heart (Aaron P. Wessell)
and a photograph of a statue from the National Museum of
the American Indian (Benjamin J. Trevias).
The two mediums were chosen deliberately to showcase
both contemporary and ancient elements to provide a dynamic
composite cover.
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2300 Eye Street, NW
Ross Hall, Suite 713-W
Washington, DC 20037

Fusion is the annual student-run scientific journal of The
George Washington University’s William H. Beaumont
Medical Research Honor Society. It was created to
showcase student achievements in basic science and
clinical research, public health, medical education, and
international health-related travel experiences.
Submissions from the classes of 2013, 2014,
and 2015, as well as the incoming class of 2016
for next year’s edition of the journal will be
accepted beginning in September 2012. For more
information, please contact the Beaumont Society at
gwbeaumont@gmail.com.
Contributions to the publishing costs of this journal
are appreciated. If you would like to make a
donation, please contact us at
gwbeaumont@gmail.com.
All proceeds will go toward
the publishing costs for next year’s journal.

